INTRODUCTION
Disseminated intravascular coagulopathy (DIC) is characterized by the systemic activation of blood coagulation and continuous generation of intravascular fibrin, which contribute to multiple organ dysfunction syndrome or other life-threating conditions [1, 2] . In the field of gastrointestinal surgery, DIC has been reported as a consequence of emergency surgery, severe com plications or some types of malignancies [35] , and as a frequent complicating factor for conditions leading to sepsis or a shock status. The acute DIC scoring system put forth by the Japanese Association for Acute Medicine (JAAM) is in widespread use for diagnosis of acute DIC [6, 7] . In order to effectively treat DIC, the underlying causes need to be improved and appropriate drugs need to be administered intensively in the earliest stage possible. However, survival rates are never high, as has been previously reported [1, 2] . In DIC, the activation of coagulation and inhibition of fibrinolysis lead to a hypercoagulable state and the deposition of fibrin in micro-vessels. Thrombomodulin-α (TM-α) is a recombinant human soluble thrombomodulin, which is a thrombin receptor on endothelial cell surfaces [810] . Thrombin binds to TM-α, and the thrombin-TM-α complex inactivates intravascular coagulation by activating the protein C pathway. The subsequent formation of thrombin and triggering of inflammatory reactions are regulated by TMα, after which hypercoagulable DIC states become improved. Therefore, TMα was approved as a curative medicine for the treatment of DIC in 2008, and its effects on DIC have been investigated in multicenter randomized clinical trials in Japan [8, 11] . Resolution rates for DIC and bleeding symptoms were found to be significantly better for patients treated with TMα than those treated with heparin [12, 13] . Previous studies have determined the efficacy of TM-α treatments for DIC associated with gastro enterological surgery [4, 5] ; however, the data are still insufficient to establish the optimal therapeutic strategies for hematological malignancies or infections such as sepsis. The optimal initiation time or duration of the administration of TM-α and the predictive factors for therapeutic efficacy remain unclear for actual clinical practice. In the present study, the treatment of DIC by TM-α in the field of gastrointestinal surgery was retrospectively summarized, and outcomes were investigated.
MATERIALS AND METHODS

Patients and treatment courses
Thirtysix patients were retrospectively investigated. Each had been diagnosed with DIC in the perioperative period and treated with TMα between January 2012 and December 2015 at the Division of Digestive Surgery in Kyoto Prefectural University of Medicine (Japan). The JAAM DIC scoring system was applied as the diagnostic criteria for DIC (DIC score ≥ 4) [6, 7] . The baseline demographics and characteristics of patients are summarized in Tables 1 and 2 . Some types of digestive cancers were the cause of DIC in 13 patients (cancer-associated).
TM-α (Recomodulin ® injection; Asahi Kasei Pharma Corporation, Tokyo, Japan) was administered intra venously at a dose of 380 U/kg per day and continued as necessary [810] . This dose was decreased to 130 U/kg in a patient with severe renal failure, according to attending physicians' decision and the manufacturer's instructions. Particularly, the patients who needed dialysis or were considered to have increased creatinine and decreased eGFR were given a reduced dose of TM-α. The duration of the administration of TM-α, and its combined usage with other treatment drugs, were also decided by the attending physicians. Clinicopathological and laboratory data obtained at 1 wk and 2 wk after the initiation of TMα administration were investigated, and the mortality rate at 28 d was determined.
This study was conducted in accordance with the principles of the Declaration of Helsinki, and written informed consent for the treatment and data collection was obtained from all patients. We did not seek individual ethical approval by the Facility of Science Committee at Kyoto Prefectural University of Medicine because this was a retrospective observational study without interpositions and with the medical practice necessary for therapeutic purposes.
Diagnostic criteria for DIC
In the present study, the following criteria were employed to diagnose DIC and compare treatment efficacies. Systemic inflammatory response syndrome (SIRS) scores were evaluated according to a previous study [14] and a SIRS score of ≥ 3 was converted to 1 point for the JAAM DIC score [7] . Quick sequential organ failure assessment (qSOFA) scores were determined by more than 1 point of altered mentation, systolic blood pressure of ≤ 100 mmHg, and respiratory rate of ≥ 22/min [15] . With respect to updates to the definitions for sepsis and septic shock criteria, sepsis was determined by more than 1 point of the qSOFA score in the present study [15] , while traditional sepsis was defined by the existence of infection and SIRS. Shock was defined by a serum lactate level of > 2 mmol/L and a requirement for vasopressors to maintain mean arterial pressure despite adequate fluid resuscitation [15] . with JAAM score of 4 or 5 (24/36, 67%). At the time of the DIC diagnosis, 5 (14%) and 14 (39%) patients did not fulfill the criteria of SIRS (≥ 2) and qSOFA (≥ 2), respectively. For most patients, TMα was administered within 1 d of the DIC diagnosis (26/36, 72%) and was continued for more than 3 d (23/36, 64%). However, 5 patients (14%) were administered TMα for only 1 d; the reasons for the discontinuation of its administration are listed in Table 3 . Although bleeding tendency was observed in 7 patients (19%), severe bleeding was not observed and a hemostatic procedure was not required. Figure 1 shows alterations in each DICassociated parameter between before and after 1 wk of the treatment in patients administered TM-α for more than 1 d. DIC scores (P = 0.003), SIRS scores (P = 0.04), qSOFA scores (P = 0.003), platelet counts (P = 0.01) and prothrombin time ratios (P = 0.006) were significantly improved after 1 wk of the treatment.
Statistical analysis
Effects of TM-α administration on DIC parameters
and compared by the stratified logrank test. A P value less than 0.05 was considered significant.
RESULTS
Baseline demographics and characteristics of patients
Clinical data of the 36 patients in this study are summarized in Tables 1 and 2 . DIC was caused by a wide variety of diseases, with abscess formation or bacteremia after surgery being the most frequent cause (12/36, 33%), followed by perforation of the digestive tract (11/36, 31%). Twentysix patients (72%) developed DIC after surgery, frequently within 1 wk of surgery (21/26, 81%). TMα was frequently used in conjunction with other drugs and treatments, such as combined administration with antithrombin concentrates, γglobulin agents, and vasopressors. Unfractionated heparins were administered to 4 patients (11%) as an alternative to TMα. A number of patients were diagnosed as having DIC Creactive protein and creatinine values were also improved (data not shown).
Survival after TM-α administration
The overall survival at 28 d for all patients administered TM-α for more than 1 d is shown in Figure 2 , and the overall survival rate was 71%. A survival analysis on some parameters is shown in Table 4 . The duration of administration (≥ 4, ≤ 6; P = 0.03) and improvements in DIC scores (P = 0.01), SIRS scores (P = 0.09) and qSOFA scores (P = 0.001) at 1 wk were significant prognostic factors for 28d survival.
Relationships between the initiation of treatment and patient demographics
In the survival analysis, patients administered TMα within 1 d of the DIC diagnosis had slightly better prognoses than those administered it after 2 d (74% vs 50%; Table 4 ). TMα was administered significantly earlier for patients with severe clinical symptoms at the time of DIC diagnosis, such as high qSOFA scores (P = 0.001), sepsis (P = 0.001), shock (P = 0.02) or high lactate values (P = 0.02) ( Table 5 ).
DISCUSSION
DIC is not prevalent in the field of gastrointestinal surgery, but it is lifethreating once it develops [4] . Early intensive care, including the administration of anti thrombin concentrates and γglobulin agents, has been shown to effectively improve the prognosis of patients with DIC [13, 16] . The early administration of TM-α has also been reported to improve severe DIC and prognoses in the field of gastrointestinal surgery [36] . In the present study, perioperative DIC patients in the field of gastrointestinal surgery who were treated with TMα were retrospectively investigated. Some DICassociated parameters, such as DIC (JAAM), SIRS and qSOFA scores, were significantly improved at 1 wk after the initiation of the TM-α treatment, and these improvements correlated with the better 28d survival rate. On the other hand, in spite of the diagnosis of DIC, the administration of TMα was significantly delayed in patients with mild symptoms, such as low SIRS or qSOFA scores, and the absence of sepsis or shock.
In order to achieve an early and accurate diagnosis of DIC, not only the counts of each parameter but also the changes in platelet counts are important. In the present study, the DIC scores of 4 patients were decided by changes in platelet counts measured in a 24h period (data not shown). DIC scores were found to increase due to decrease in platelet counts of > 30% or 50% in a 24h period, and further reductions of platelet counts were observed on the next day. Therefore, the rate of decreases in platelet counts is also important for reaching an early decision on the DIC score.
In the survival analysis, the overall survival rate at 28 d (71%) was similar to previous findings [4] . On the other hand, the survival rate of patients administered TM-α at 2 d after the DIC diagnosis was slightly worse (74% vs 50%). Early treatments, including TMα, are generally considered to be advantageous for improving the prognosis of DIC patients [5, 6, 10] . In the present study, the administration of TMα was significantly delayed (by more than 1 d after the DIC diagnosis) in patients who were less symptomatic (i.e., not meeting the criteria of qSOFA, sepsis or shock and having low lactate values). Therefore, early and accurate diagnosis of DIC and initiation of treatments will be needed for all patients with mild symptoms who are suspected of having DIC.
The definitions of sepsis and shock were recently revised [15] . Previously, traditional sepsis had been defined as the presence of infection and SIRS, but it is now defined by an increase in the SOFA score (≥ 2). Moreover, shock is defined by a requirement for vasopressors and enhanced serum lactate levels (> 2 mmol/L). In the present study, we used qSOFA scores exclusively because we were unable to confirm all data to provide an accurate SOFA score. The indication of TM-α administration is decided by the JAAM DIC score (≥ 4) only, and these DIC patients frequently present with accompanying severe complications such as shock or sepsis [2, 1316] . It remains controversial whether these severe conditions can influence the therapeutic effects of DIC. In the present study, the parameters showing severe conditions were also investigated, but were found to not significantly affect the efficacy of TMα or prognosis of patients. The present study had some limitations. The number of patients examined was small because DIC is not prevalent in the field of gastrointestinal surgery. Furthermore, DIC scores were retrospectively evaluated by only the JAAM acute DIC scoring system, and we did not confirm that the attending physicians gave accurate DIC scores at diagnosis. In the future, the comparisons with other criteria, such as the Inter national Society for Thrombosis and Haemostasis DIC score, will be needed. In previous studies, DIC patients treated with TMα for approximately 6 d have been commonly evaluated [4, 10] , while patients in the present study were treated for shorter or longer durations. Some of our patients who were administered TMα for a shorter duration showed amelioration of the DIC, whereas many patients with a shorter or longer duration of administration had worse prognoses. A 6d administration is needed if patient conditions permit it, and the advantages and disadvantages of the early discontinuation of administration due to improvements in DIC require further investigations. Another limitation is that all patients in this study were treated with TMα and other drugs, and comparisons of the efficacy of the treatments, prognosis of patients or development of side effects between TMα and the other drugs were not performed.
In conclusion, although the number of patients examined in the present study was small, we herein demonstrated that the early diagnosis of DIC and initiation of the TM-α administration are effective for achieving improvements in DIC in the field of gastro intestinal surgery. The diagnosis of patients with mild symptoms requires further study.
COMMENTS
Background
Disseminated intravascular coagulopathy (DIC) has been reported in the field of gastrointestinal surgery as a consequence of emergency surgery, severe complications or some types of malignancies, and has been shown to frequently complicate conditions leading to sepsis or a shock status. In order to effectively treat DIC, the underlying causes need to be resolved, or at least improved, and appropriate drugs need to be administered intensively at earlier stage. However, survival rates are never high, as has been reported consistently.
Research frontiers
Thrombomodulin-α (TM-α) was approved as a curative medicine for the treatment of DIC, and previous studies have reported its efficacy for DIC associated with gastrointestinal surgery. However, the data are still insufficient to establish optimal therapeutic strategies. The research hotspot is the introduction of an optimized treatment with TM-α and identification and clinical application of predictive factors to improve therapeutic efficacy of DIC in the field of gastrointestinal surgery.
Innovations and breakthroughs
DIC is not prevalent in the field of gastrointestinal surgery, but is life-threating once it develops. In the present study, some DIC-associated parameters, such as DIC (Japanese Association for Acute Medicine), systemic inflammatory response syndrome (SIRS) and quick-sequential organ failure assessment (qSOFA) scores, were significantly improved at 1 wk after the initiation of TM-α treatment, and these improvements correlated with better 28-d survival. Early diagnosis of DIC and initiation of the TM-α administration are effective for achieving improvements in DIC in the field of gastrointestinal surgery. On the other hand, in spite of DIC diagnosis, administration of TM-α was significantly delayed in patients with mild symptoms, such as low SIRS or qSOFA scores, and the absence of sepsis or shock.
Applications
The data in this study suggested that early diagnosis of DIC and initiation of the TM-α administration are clinically effective for DIC treatment in the field of gastrointestinal surgery. Furthermore, this study also provided readers with important information regarding the delay of TM-α administration for less symptomatic DIC patients.
Terminology
DIC leads to a hypercoagulable state and the deposition of fibrin in microvessels. TM-α is a recombinant human soluble thrombomodulin, which is a thrombin receptor on endothelial cell surfaces. Thrombin binds to TM-α, and the thrombin-TM-α complex inactivates intravascular coagulation by activating the protein C pathway. Therefore, the further formation of thrombin and triggering of inflammatory reactions are regulated by TM-α, and hypercoagulable DIC states are improved.
Peer-review
This manuscript reports on the early diagnosis and earlier initiation of recombinant thrombomodulin for DIC patients in the field of digestive surgery. Identification of an optimized treatment with TM-α and clinical application of predictive factors will be very useful for DIC treatment, improving the therapeutic efficacy.
